Acne News and Research RSS Feed - Acne News and Research

Acne is a disorder resulting from the action of hormones and other substances on the skin's oil glands (sebaceous glands) and hair follicles. These factors lead to plugged pores and outbreaks of lesions commonly called pimples or zits. Acne lesions usually occur on the face, neck, back, chest, and shoulders. Although acne is usually not a serious health threat, it can be a source of significant emotional distress. Severe acne can lead to permanent scarring.
Galderma obtains FDA approval for Restylane Lyft to restore structure to the cheeks and midface area

Galderma obtains FDA approval for Restylane Lyft to restore structure to the cheeks and midface area

Galderma, a global healthcare company focused on skin health, announced today that it has received U.S. Food and Drug Administration approval to market Restylane Lyft for cheek augmentation and the correction of age-related midface contour deficiencies in patients over the age of 21. [More]
Celtaxsys closes $40M Series D financing and receives $5M CFFT grant to conduct CTX-4430 Phase 2 trial

Celtaxsys closes $40M Series D financing and receives $5M CFFT grant to conduct CTX-4430 Phase 2 trial

Celtaxsys, Inc., a clinical stage drug development company focused on developing novel therapies for inflammatory diseases, today announced the successful completion of a $40M Series D financing led by Domain Partners VIII. Additional investors in the financing include Lumira Capital, RMI Partners, Masters Capital Management and the Georgia Research Alliance Venture Fund. [More]
Zapne offers better alternative to available acne treatments

Zapne offers better alternative to available acne treatments

After a decade of research, Zapne LLC has released its signature acne treatment, Zapne, an all-natural product to treat acne without the harsh side effects of many current regimens. Zapne offers four key advantages over most acne treatments: The treatment system is formulated from natural, non-synthetic ingredients, produces no material side effects, requires only a single 15-minute weekly application, and produces visible results quickly, in some cases after only one or a few applications. [More]
ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Novartis today announced new data from two Phase II studies of Zykadia (ceritinib), as well as one Phase II study of Tafinlar® (dabrafenib) in combination with Mekinist (trametinib) in certain patients with non-small cell lung cancer. [More]
Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy. Treatment with afatinib significantly reduced the risk of death by 19%, extending the survival of patients to a median of 7.9 months compared to 6.8 months on erlotinib. [More]
Combination of Mekinist and Tafinlar drugs improves outcome in patients with metastatic melanoma

Combination of Mekinist and Tafinlar drugs improves outcome in patients with metastatic melanoma

Novartis today announced data from the Phase III COMBI-d study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive metastatic melanoma when treated with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) compared to Tafinlar monotherapy alone. [More]
Combination of contraceptive and cholesterol-lowering drugs kills cancer cells in a new way

Combination of contraceptive and cholesterol-lowering drugs kills cancer cells in a new way

The combination of a cholesterol-lowering drug, Bezafibrate, and a contraceptive steroid, Medroxyprogesterone Acetate, could be an effective, non-toxic treatment for a range of cancers, researchers at the University of Birmingham have found. [More]

Cipher strengthens Canadian dermatology portfolio with acquisition of Vaniqa, Actikerall

Cipher Pharmaceuticals Inc. today announced it has strengthened its Canadian dermatology portfolio by acquiring the Canadian rights to Vaniqa and Actikerall from Almirall S. A., a Spanish pharmaceutical company. Both products have been approved by Health Canada. [More]
New web-based platform launched to provide acne care to patients across Pennsylvania

New web-based platform launched to provide acne care to patients across Pennsylvania

Dr. Jamie Altman, owner and president of Aesthetic Dermatology Associates, PC, a dermatology practice based in the Philadelphia suburbs of Media and Paoli, today announced the launch of AcneCareMD.com, a secure telemedicine website designed to provide acne care to patients across Pennsylvania via a web-based platform. [More]
New targeted therapy promises to reduce frequency and intensity of breakouts

New targeted therapy promises to reduce frequency and intensity of breakouts

Acne, a scourge of adolescence, may be about to meet its ultra high-tech match. By using a combination of ultrasound, gold-covered particles and lasers, researchers from UC Santa Barbara and the private medical device company Sebacia have developed a targeted therapy that could potentially lessen the frequency and intensity of breakouts, relieving acne sufferers the discomfort and stress of dealing with severe and recurring pimples. [More]
Cipher to distribute Can-Fite’s CF101 for plaque psoriasis and rheumatoid arthritis treatment in Canada

Cipher to distribute Can-Fite’s CF101 for plaque psoriasis and rheumatoid arthritis treatment in Canada

Cipher Pharmaceuticals Inc. today announced it has licensed the Canadian distribution rights to CF101, a novel chemical entity being developed by Can-Fite Biopharma for moderate to severe plaque psoriasis and rheumatoid arthritis. [More]
Can-Fite, Cipher Pharmaceuticals sign agreement to distribute CF101 in Canada

Can-Fite, Cipher Pharmaceuticals sign agreement to distribute CF101 in Canada

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has signed a distribution agreement with Cipher Pharmaceuticals Inc. to distribute Can-Fite's lead drug candidate, CF101, for the treatment of moderate to severe psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals. [More]

Acne patients not getting medications prescribed by their dermatologists

Medicine obviously can't do much good if it sits on a pharmacy shelf. Yet more than one-quarter of the acne patients surveyed by Wake Forest Baptist Medical Center researchers didn't get medications prescribed by their dermatologists. [More]
Study: Blood tests for women taking spironolactone to treat hormonal acne are unnecessary

Study: Blood tests for women taking spironolactone to treat hormonal acne are unnecessary

A new study by researchers at Brigham and Women's Hospital has found that for young, healthy women taking spironolactone to treat hormonal acne, frequent office visits and blood draws are an unnecessary health care expense. [More]

Canfield to become sole supplier of PRIMOS family of 3D optical systems worldwide

Demonstrating its commitment to delivering best-in-class clinical research solutions, Canfield Scientific has been named the exclusive worldwide distributor of the highly respected PRIMOS family of 3D optical systems. [More]

Alma Lasers launches Harmony XL Pro platform to address aesthetic concerns of patients

Alma Lasers, a global innovator of laser, light-based, radiofrequency and ultrasound solutions for the aesthetic and surgical markets announced the addition of the Harmony XL Pro platform to its product portfolio. [More]

Envy Medical launches world-class patented Advanced Dermalinfusion Technology

Envy Medical, Inc. launches SilkPeel3, the next generation of its world class patented Advanced Dermalinfusion Technology. Unveiled originally in 2005, SilkPeel is celebrating its 10th birthday in style with fresh features, enhanced functionality and a sleek new design. [More]
Blunted cortisol response common in non-classic CAH

Blunted cortisol response common in non-classic CAH

Nearly two-thirds of children with non-classic congenital adrenal hyperplasia have an inadequate cortisol response, report researchers. [More]
FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

Actavis plc, a leading global specialty pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company, today announced the approval of LILETTA (levonorgestrel-releasing intrauterine system) by the U.S. Food and Drug Administration for use by women to prevent pregnancy for up to three years. [More]
Cipher acquires worldwide rights to three products from Astion

Cipher acquires worldwide rights to three products from Astion

Cipher Pharmaceuticals Inc. today announced it has strengthened its product pipeline by acquiring the worldwide rights to three products from Astion Pharma, a Denmark-based specialty pharmaceutical company. [More]
Advertisement